Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ANTA PHAR       

ANTA PHAR
Mes dernières consult.
Most popular
  Report  
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 -
EBIT 2017 -36,4 M
Net income 2017 -30,5 M
Debt 2017 -
Yield 2017 -
Sales 2018 8,93 M
EBIT 2018 -36,1 M
Net income 2018 -35,7 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 0
Capi. / Sales2018 2,62x
Capitalization 23,4 M
More Financials
Company
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines to treat serious and life threatening diseases.It offers Sollpura and blisibimod to treat diseases such as exocrine pancreatic insufficiency and Immunoglobulin A... 
More about the company
Surperformance© ratings of ANTA PHAR
Trading Rating : Investor Rating :
More Ratings
Latest news on ANTA PHAR
09:16pANTHERA PHARMACEUTICALS : Why Shares of Anthera Pharmaceuticals are Soaring
AQ
02/09ANTHERA PHARMACEUTICALS : to participate in the BIO CEO and Investor Conference ..
AQ
02/08Anthera Pharmaceuticals to Participate in the BIO CEO & Investor Conference a..
GL
02/06ANTHERA PHARMACEUTICALS : Concludes Last Patient Visit in the Phase 3 RESULT Cli..
AQ
02/05Anthera Concludes Last Patient Visit in the Phase 3 RESULT Clinical Study of ..
GL
01/29ANTHERA PHARMACEUTICALS : Receives Positive Nasdaq Listing Determination
AQ
01/26ANTHERA PHARMACEUTICALS,INC. (NASDAQ : ANTH) Files An 8-K Notice of Delisting or..
AQ
01/25ANTHERA PHARMACEUTICALS INC : Notice of Delisting or Failure to Satisfy a Contin..
AQ
01/25Anthera Receives Positive Nasdaq Listing Determination
GL
01/25ANTHERA PHARMACEUTICALS INC : Today’s Research Reports on Trending Tickers: Anth..
AC
More news
Sector news : Bio Therapeutic Drugs
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
02/14BRISTOL MYERS SQUIBB : Nektar to Partner on Cancer Therapy
DJ
02/13Drug copies ready to take next bite out of Roche's cancer sales
RE
More sector news : Bio Therapeutic Drugs
Income Statement Evolution
Consensus
 
Mean consensus HOLD
Number of Analysts 5
Average target price 2,44 $
Spread / Average Target 44%
EPS Revisions
Managers
NameTitle
John Craig Thompson President, CEO & Executive Director
Paul F. Truex Executive Chairman
May Liu CAO, Senior VP-Finance & Administration
William R. Shanahan Chief Medical Officer
David E. Thompson Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ANTA PHAR23
GILEAD SCIENCES14.21%105 702
VERTEX PHARMACEUTICALS4.94%40 647
REGENERON PHARMACEUTICALS-12.04%35 686
BIOVERATIV INC91.99%11 211
GENMAB4.28%10 637